BABA is at $68 is very expensive, more expensive than AMZN. Expecting big guys to short it and push the market down.
If it breaks $10.90 then it may go to $10.75.
The price is low enough for buyback some shares, say 1 million shares this week.
Non, 5 years, 2 years and 1 year average price is between $60 to $70. Current price is the low of several years. It won't last since SINA is growing revenue at very high rate. The only reason for this depressed price is China government which SINA will work out a deal soon.
So, take advantage of these low prices while other stocks have reached unsustainable high prices. You cannot find any good deal like SINA at this time.
SINA will go up with high probability while the chance of lower prices are very very small or none.
Don't worry, it will be $8.50 and higher and then we have to remind you current prices where you should be buying instead of wasting your time about up or down.
This is not the first time and this will not be the last time to deal with government (China). SINA resolved it in past and it will resolve it this time too.
This happened because of inexperience and vision. The company marketing is doing well but when come to this acquisition, the marketing cannot compensate for it. To compare it with V drug, HZNP could buy 13 drugs. Well, shareholders would be happy with at least 5 drugs.
1. My pay is rising, you voted for me.
2. The higher my pay, the lower my productivity.
3. The pay’s great and I have job security with tons of cash in company position.
4. I’ll cash out some options at the first opportunity.
5. Even my own executives doubt me…
6. …but I’m chummy.
7. I belong to a boy’s club.
8. there is not any activist shareholders to pull my strings.
9. The public may be on my case but I do not care.
10. I know you don’t trust me.
So, when development was stopped then the company should know how to buy and sell drugs. The company is given a high premium for a reason, either a blockbuster drug will be develop or the company is marketing genius to sell existing drugs. If neither happens then it should be a penny stock.
If you say 28 months or 9 quarter and each quarter of $50 m, it translates in $450 m.
Anyway, after the taxes, $240 becomes only $182 m. SLXP is more smarter than DEPO.
What is the purpose of $182 if it is not deployed for growth? A good company has several current and future plans but not depo that is waiting something drops in its basket. It depo had a plan then it should have issued $300 to $500 bonds when the stock was in $15s at higher prices like $17 to $20, buy a company or a few targeted drugs and push the price to over $20. But that takes a management with vision and plan.
Depo has become a drug seller but a development biotech. And if a drug seller does not know how to sell and market its drugs then it becomes a company like depo. The cash won't do anything if you do not know how to use or you are in business to secure your job for a while and that is what depo management is doing.
First, it was speculation of some lawsuits.
Second, it was an accounting error.
Third, it way JPM reduced revenue.
You see, all above have not affected or a tiny effect on BAC income, however paid media has made a big deal out of the news. Mötley fool, the useless media, repeats accounting error almost daily with no substances.
BAC will go back to $20s sooner or later and investors with patience will be rewarded eventually.
Both JPM and BAC are cheap at current prices. JPM rev is ok. The rev will grow after the trading rev settles in near future. Trading rev has been volatile for all banks. In a period, they do well and when economy slows down then trading rev goes down. Trading rev is a very small portion of total rev anyway.
When they sell every single day then what do expect the price is heading. Almost 1/2 of shares are dumped by Ueno, wife and his private company. He. Issued almost all shares to himself when he was in charge.